[Abstract Only] In a Phase 2 randomized trial, Semaglutide at high doses improved Nonalcoholic Steatohepatitis (NASH), but with no significant beneficial effects in liver fibrosis

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Semaglutide Shows Promise in NASH Phase 2 Study – Medscape (free registration required)

Commentary on Twitter

Patients with nonalcoholic steatohepatitis were randomly assigned to receive subcutaneous semaglutide or placebo. The incidence of NASH resolution was significantly higher with semaglutide than with placebo. #LiverMtg20

— NEJM (@NEJM) November 13, 2020